Formoso Giulio, Font-Pous Maria, Ludwig Wolf-Dieter, Phizackerley David, Bijl Dick, Erviti Juan, Pospíšilová Blanka, Montastruc Jean Louis
Health and Welfare Directorate, Emilia-Romagna, Bologna, Italy.
Pharmaceutical department, ULSS 20 Verona, Italy.
Health Policy. 2017 Mar;121(3):257-264. doi: 10.1016/j.healthpol.2016.12.007. Epub 2016 Dec 29.
To evaluate the framework of drug information produced by public health and regulatory institutions in Europe.
We carried out a short survey asking editors of ISDB bulletins of the European region to indicate the main sources of drug information provided by public health and regulatory authorities in their countries, the specific kind of information produced and their opinions about strengths and weaknesses of such information. The availability of evaluations about the added therapeutic value of drugs and of tools facilitating the implementation of such information were particularly addressed and checked on the websites of those institutions.
Answers pertaining to eight countries were available. Regulatory information and safety alerts are generally available, but just UK and Germany stand out by showing quite an advanced framework of evidence-based, comparative drug information for health professionals, decision-makers and for the general public. National plans to implement evidence-based drug information seem lacking.
More efforts are warranted to develop sharp formats to make evidence-based drug information easier to access, understand and put in context, showing the place in therapy of medicines and their added therapeutic value. Harmonization of different sources, also at European level, would be important to favor their access and limit dispersion. Appropriate tools and specific plans are then necessary to favor implementation of information materials.
评估欧洲公共卫生和监管机构产生的药物信息框架。
我们进行了一项简短调查，要求欧洲地区《国际药物通报》的编辑指出其所在国家公共卫生和监管当局提供的药物信息的主要来源、所产生的具体信息类型以及他们对这类信息优缺点的看法。特别关注并在这些机构的网站上检查了关于药物附加治疗价值评估的可用性以及促进此类信息实施的工具。
获得了与八个国家相关的答复。监管信息和安全警报普遍可得，但只有英国和德国脱颖而出，展示了一个相当先进的、针对卫生专业人员、决策者和普通公众的循证、比较药物信息框架。国家实施循证药物信息的计划似乎缺乏。
有必要做出更多努力来开发清晰的形式，使循证药物信息更易于获取、理解并置于背景中，展示药物在治疗中的地位及其附加治疗价值。在欧洲层面协调不同来源也很重要，这有利于获取信息并限制分散。然后需要适当的工具和具体计划来促进信息材料的实施。
